Suggestions
Mark Cobbold
VP of Oncology Early Discovery at AstraZeneca
Mark Cobbold is a prominent figure in the field of oncology and immunotherapy, currently serving as the VP of Oncology Early Discovery at AstraZeneca, a position he has held since September 2019.1 With over 500 connections on LinkedIn, Cobbold is based in the Greater Boston Area.1
Professional Experience
Cobbold's career is marked by significant contributions to both academia and industry:
Industry Roles::
- VP Oncology Early Discovery at AstraZeneca (September 2019 - Present)1
- Scientific Co-Founder of multiple biotech companies, including:
- GigaMune (January 2019 - Present)
- Gritstone Oncology (October 2015 - Present)
- Revitope (November 2014 - Present)
- PhosImmune, Inc. (September 2012 - June 2015)
- Serascience (May 2011 - June 2015)1
Academic Positions::
- Associate Member at the Broad Institute (September 2015 - September 2019)
- Associate Professor at Massachusetts General Hospital (June 2015 - September 2019)
- Associate Professor of Medicine at Harvard University (June 2015 - September 2019)
- Reader in Translational Immunology at the University of Birmingham (March 2014 - May 2015)1
Research Focus
Cobbold's work primarily revolves around immuno-oncology (IO) and cell therapy research:
- He is actively involved in advancing cancer medicines through collaboration and knowledge sharing.3
- Cobbold has been instrumental in AstraZeneca's efforts to harness the benefits of cell therapies for solid tumors.4
- He has highlighted the company's immuno-oncology research at conferences like SITC (Society for Immunotherapy of Cancer).5
Education
Cobbold holds a PhD in Immunology/Immunotherapy from the University of Birmingham, which he completed between 2000 and 2003.1
Thought Leadership
As a thought leader in his field, Cobbold regularly shares insights on:
- The complexities of the immune system and how cancer can hijack it2
- The future of immunotherapy in oncology7
- The role of immuno-oncology and cell therapy in cancer treatment6
Through his work at AstraZeneca and his contributions to various biotech startups, Mark Cobbold continues to play a significant role in shaping the future of cancer treatment, particularly in the areas of immuno-oncology and cell therapy.
Highlights
I am thrilled to share the exciting news that Gracell Biotechnologies was nominated as one of the Annual Top 50 Most Innovative Enterprises in the Biopharma Industry in China, and has received the prestigious Pharma BIG Star award! This is a tremendous achievement and a testament to the efforts, dedication, and innovation of Gracell’s entire team. The cell therapy pioneers joined the AstraZeneca organization earlier this year and it’s a privilege to be working with such a talented and passionate team as we continue to push the boundaries of science.
I couldn’t be at #ASCO2024 in person this year, but it was great to see from afar that the global drive to fight cancer shows no sign of letting up.
AstraZeneca showcased continued progress across our oncology portfolio including cell therapy. I was sorry to miss an oral presentation of exciting data from our collaboration with AbelZeta, showing the early potential of our innovative CAR-T armoring platform, that is designed to overcome immunosuppression in solid tumors. And the first preclinical data from Neogene Therapeutics’ newest T cell receptor therapy was also on display.
These developments underscore our ambition to deliver on the promise of cell therapy across more types of cancer, including solid tumors, by building better T cells to overcome current treatment challenges.
Learn more about our research in cell therapy in this blog I co-authored with Gordon Moody: https://lnkd.in/eUb8Gs3N
#Oncology #WhatScienceCanDo #CAR-T #CellTherapy
